Lung Sarcomatoid Carcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

Sources

Aliases & Classifications for Lung Sarcomatoid Carcinoma

MalaCards integrated aliases for Lung Sarcomatoid Carcinoma:

Name: Lung Sarcomatoid Carcinoma ¹¹ ¹⁴ ¹⁶

Sarcomatoid Carcinoma of the Lung ¹¹ ⁷⁵

Pulmonary Sarcomatoid Carcinoma ¹¹

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Respiratory diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹¹ DOID:0080777

NCIt ⁴⁹ C45540

EFO ¹⁶ EFO_1000336

Sources

Summaries for Lung Sarcomatoid Carcinoma

Disease Ontology: ¹¹ A lung carcinoma that is characterized by the presence of a sarcomatoid component often associated with giant cell differentiation.

MalaCards based summary: Lung Sarcomatoid Carcinoma, also known as sarcomatoid carcinoma of the lung, is related to pulmonary blastoma and small cell cancer of the lung. An important gene associated with Lung Sarcomatoid Carcinoma is KDM4C (Lysine Demethylase 4C), and among its related pathways/superpathways are Signal Transduction and RAF/MAP kinase cascade. The drugs Durvalumab and Tremelimumab have been mentioned in the context of this disorder. Affiliated tissues include lung, lymph node and spinal cord, and related phenotypes are Decreased viability and neoplasm

Wikipedia: ⁷⁵ Sarcomatoid carcinoma of the lung is a term that encompasses five distinct histological subtypes of lung... more...

Sources

Related Diseases for Lung Sarcomatoid Carcinoma

Diseases related to Lung Sarcomatoid Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 451)

#	Related Disease	Score	Top Affiliating Genes
1	pulmonary blastoma	30.9	NKX2-1 KRAS EGFR
2	small cell cancer of the lung	30.8	NKX2-1 KRT7 EGFR
3	sarcomatoid mesothelioma	30.4	KRT5 CALB2
4	bronchus cancer	30.3	KRT7 EGFR ALK
5	carcinosarcoma	30.2	KRT7 KRAS HRAS EGFR CD274 CALB2
6	angiosarcoma	30.2	ROS1 KRAS CALB2
7	benign mesothelioma	30.2	NKX2-1 KRT7 KRT5 CALB2
8	appendix adenocarcinoma	30.2	KRT7 KRAS HRAS
9	exanthem	30.1	KRAS HRAS EGFR CD274 ALK
10	lung squamous cell carcinoma	29.9	KRAS HRAS EGFR CD274 ALK
11	blastoma	29.9	RET NKX2-1 KRT7 KRAS HRAS EGFR
12	lung giant cell carcinoma	29.9	NKX2-1 NAPSA KRT7 KRT5 KRAS EGFR
13	small intestine cancer	29.8	KRT7 KRAS HRAS EGFR CD274
14	pleural disease	29.8	KRT5 EGFR CD274 CALB2 ALK
15	leukemia, chronic lymphocytic	29.7	KRAS KDM4C HRAS EGFR CD274 ALK
16	leukemia, acute myeloid	29.7	KRAS KDM4C HRAS EGFR CD274 ALK
17	mesothelioma, malignant	29.6	NKX2-1 MET KRT7 KRT5 CALB2
18	malignant pleural mesothelioma	29.6	MET HRAS EGFR CD274 CALB2
19	squamous cell carcinoma	29.5	NKX2-1 KRT7 KRAS KDM4C HRAS EGFR
20	small cell carcinoma	29.5	NKX2-1 NAPSA KRT7 KRT5 EGFR ALK
21	mixed cell type cancer	29.5	KRT7 KRT5 KRAS HRAS EGFR CALB2
22	sarcoma	29.4	ROS1 MET KRAS HRAS CALB2 ALK
23	lung benign neoplasm	29.4	NKX2-1 MET KRT7 KRAS HRAS EGFR
24	adenosquamous carcinoma	29.3	NKX2-1 KRT7 KRT5 KRAS HRAS EGFR
25	mucinous adenocarcinoma	29.2	ROS1 NKX2-1 NAPSA KRT7 KRAS HRAS
26	rhabdomyosarcoma	29.0	RET MET KRT7 KRAS HRAS EGFR
27	pleomorphic carcinoma	28.9	ROS1 NKX2-1 NAPSA KRT7 KRT5 KRAS
28	wilms tumor 1	28.8	NKX2-1 KRT7 KRT5 KRAS KDM4C HRAS
29	large cell neuroendocrine carcinoma	28.7	ROS1 NKX2-1 NAPSA KRT7 KRT5 KRAS
30	large cell carcinoma	28.4	ROS1 NKX2-1 NAPSA KRT7 KRT5 KRAS
31	lung cancer susceptibility 3	28.3	ROS1 NKX2-1 NAPSA MET KRT7 KRAS
32	adenocarcinoma	28.2	ROS1 RET NKX2-1 NAPSA MET KRT7
33	lung cancer	28.0	ROS1 RET NKX2-1 NAPSA MET KRT7
34	renal cell carcinoma, nonpapillary	27.9	RET NKX2-1 NAPSA MET KRT7 KRAS
35	pleuropulmonary blastoma	10.4
36	lung sarcoma	10.4	CALB2 ALK
37	fibrous histiocytoma	10.4
38	cutaneous fibrous histiocytoma	10.4
39	pulmonary plasma cell granuloma	10.3	ROS1 ALK
40	heart leiomyosarcoma	10.3	EGFR ALK
41	urethra transitional cell carcinoma	10.3	EGFR ALK
42	malignant giant cell tumor of the tendon sheath	10.3	ROS1 ALK
43	gray zone lymphoma	10.3	KDM4C CD274
44	benign fibrous mesothelioma	10.3	CALB2 ALK
45	liver leiomyoma	10.3	CALB2 ALK
46	trachea carcinoma in situ	10.3	KRAS HRAS
47	malignant fibrous histiocytoma	10.3
48	fibrosarcoma	10.3
49	common bile duct neoplasm	10.3	KRAS HRAS
50	composite lymphoma	10.3	KDM4C CD274

Graphical network of the top 20 diseases related to Lung Sarcomatoid Carcinoma:

Sources

Symptoms & Phenotypes for Lung Sarcomatoid Carcinoma

GenomeRNAi Phenotypes related to Lung Sarcomatoid Carcinoma according to GeneCards Suite gene sharing:

²⁵ (show all 13)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Decreased viability	GR00055-A-1	9.78	EGFR HRAS KRAS
2	Decreased viability	GR00055-A-2	9.78	EGFR HRAS KRAS
3	Decreased viability	GR00055-A-3	9.78	KRAS
4	Decreased viability	GR00106-A-0	9.78	KRAS
5	Decreased viability	GR00221-A-1	9.78	ALK EGFR HRAS KRAS RET ROS1
6	Decreased viability	GR00221-A-2	9.78	HRAS KRAS RET ROS1
7	Decreased viability	GR00221-A-3	9.78	HRAS
8	Decreased viability	GR00221-A-4	9.78	ALK EGFR RET
9	Decreased viability	GR00249-S	9.78	ALK ROS1
10	Decreased viability	GR00301-A	9.78	KRAS RET
11	Decreased viability	GR00342-S-1	9.78	ROS1
12	Decreased viability	GR00381-A-1	9.78	KRAS
13	Decreased viability	GR00402-S-2	9.78	RET

MGI Mouse Phenotypes related to Lung Sarcomatoid Carcinoma:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	neoplasm	MP:0002006	9.92	ALK EGFR HRAS KDM4C KRAS MET
2	normal	MP:0002873	9.86	ALK CALB2 EGFR HRAS KRAS MET
3	no phenotypic analysis	MP:0003012	9.81	CD274 EGFR HRAS KDM4C KRAS MET
4	digestive/alimentary	MP:0005381	9.5	EGFR HRAS KRAS KRT5 MET NKX2-1
5	respiratory system	MP:0005388	9.17	ALK EGFR HRAS KRAS MET NKX2-1

Sources

Drugs & Therapeutics for Lung Sarcomatoid Carcinoma

Drugs for Lung Sarcomatoid Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 25)

#

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

1

Durvalumab

Approved, Investigational

Phase 2

1428935-60-7

2

Tremelimumab

Approved, Investigational

Phase 2

745013-59-6

3

Coenzyme M

Approved, Investigational

Phase 2

3375-50-6

598 23662354

4

Ifosfamide

Approved

Phase 2

3778-73-2

3690

5

Doxorubicin

Approved, Investigational

Phase 2

23214-92-8

31703

6

Nivolumab

Approved

Phase 2

946414-94-4

7

Ipilimumab

Approved

Phase 2

477202-00-9

8

Carboplatin

Approved

Phase 2

41575-94-4

10339178 38904

9

Bevacizumab

Approved, Investigational

Phase 2

216974-75-3

135329020

10

Paclitaxel

Approved, Vet_approved

Phase 2

33069-62-4

36314

11

Palifosfamide

Investigational

Phase 2

31645-39-3

100427

12

Anti-Bacterial Agents

Phase 2

13

Alkylating Agents

Phase 2

14

Antineoplastic Agents, Alkylating

Phase 2

15

Antibiotics, Antitubercular

Phase 2

16

Liposomal doxorubicin

Phase 2

17

Immunoglobulins

Phase 2

18

Immune Checkpoint Inhibitors

Phase 2

19

Antibodies, Monoclonal

Phase 2

20

Antibodies

Phase 2

21

Antineoplastic Agents, Immunological

Phase 2

22

Albumin-Bound Paclitaxel

Phase 2

23

Antimitotic Agents

Phase 2

24

Angiogenesis Inhibitors

Phase 2

25

Tubulin Modulators

Phase 2

Interventional clinical trials:

#	Name	Status	NCT ID	Phase	Drugs
1	Phase II Study of Durvalumab + Tremelimumab in Pulmonary Sarcomatoid Carcinoma	Unknown status	NCT03022500	Phase 2	durvalumab + tremelimumab
2	Phase II Study of Durvalumab ,Doxorubicin, and Ifosfamide in Pulmonary Sarcomatoid Carcinoma	Unknown status	NCT04224337	Phase 2	Durvalumab + doxorubicin + ifosfamide
3	DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors	Recruiting	NCT02834013	Phase 2
4	A Single-arm Exploratory Clinical Study on the Efficacy and Safety of Toripalimab Combined With Bevacizumab, Nab-paclitaxel and Carboplatin for Untreated Metastatic Pulmonary Sarcomatoid Carcinoma	Recruiting	NCT04725448	Phase 2	Toripalimab;Bevacizumab;Nab-paclitaxel;Carboplatin
5	A Phase II, Open-label Study to Evaluate the Efficacy and Safety of HMPL-504 in Locally Advanced/Metastatic MET-Mutation-Positive Pulmonary Sarcomatoid Carcinomas and Other Non-small Cell Lung Cancer	Active, not recruiting	NCT02897479	Phase 2	Savolitinib
6	Integrative Analysis of Pulmonary Sarcomatoid Carcinoma (PSC)	Not yet recruiting	NCT04215913

Search NIH Clinical Center for Lung Sarcomatoid Carcinoma

Sources

Genetic Tests for Lung Sarcomatoid Carcinoma

Sources

Anatomical Context for Lung Sarcomatoid Carcinoma

Organs/tissues related to Lung Sarcomatoid Carcinoma:

MalaCards : Lung, Lymph Node, Spinal Cord, Tongue, Neutrophil, Pineal, Brain

Sources

Publications for Lung Sarcomatoid Carcinoma

Articles related to Lung Sarcomatoid Carcinoma:

(show top 50) (show all 261)

#	Title	Authors	PMID	Year
1	The Correlation Between Histologic, Immunophenotypic, and Molecular Characteristics of Pulmonary Sarcomatoid Carcinoma Reveals That Sarcomatoid Change Is Potentially Derived From Epithelial Carcinoma Cells Undergoing Epithelial-Mesenchymal Transition. ⁶²	Huang Y...Hou L	36165833	2023
2	Partial response to pralsetinib in an advanced pulmonary sarcomatoid carcinoma patient harboring a KIF5B-RET rearrangement: a case report. ⁶²	Wu Y...Nie X	36471407	2022
3	Analysis of molecular pathologic and clinical features of 36 patients with pulmonary sarcomatoid carcinoma. ⁶²	Yu Y...Wu D	36447228	2022
4	Factors Associated With Lymph Node Yield and Effects of Lymph Node Density on Survival of Patients With Pulmonary Sarcomatoid Carcinoma. ⁶²	Huang L...Lyu J	36256867	2022
5	The prognostic impact of immune checkpoint inhibitors for the treatment of pulmonary sarcomatoid carcinoma: A multicenter retrospective study. ⁶²	Wei JW...Song ZB	36353935	2022
6	Synchronal pulmonary sarcomatoid carcinoma and lung adenocarcinoma EML4-ALK fusion: A case report. ⁶²	Wang M...Lei X	36072009	2022
7	Long-Term Efficacy, Safety, and Subgroup Analysis of Savolitinib in Chinese Patients With NSCLCs Harboring MET Exon 14 Skipping Alterations. ⁶²	Lu S...Su W	36217329	2022
8	Clinical analysis of 78 pulmonary sarcomatoid carcinomas with surgical treatment. ⁶²	Gong T...Wang C	36224744	2022
9	Clinical characteristics and prognostic factors of pulmonary sarcomatoid carcinoma. ⁶²	Zhao C...Mu J	36389311	2022
10	Adjuvant chemotherapy could improve the survival of pulmonary sarcomatoid carcinoma: A systematic review and meta-analysis. ⁶²	Zombori-Toth N...Zombori T	35952403	2022
11	Anlotinib combined with chemotherapy and immunotherapy for advanced pulmonary sarcomatoid cancer: a case report and literature review. ⁶²	Piao MN...Wang JP	36267791	2022
12	PSC subtyping based on TTF-1 and p40 expression reveals distinct molecular characteristics and therapeutic strategies. ⁶²	Yang Z...He J	35612583	2022
13	Transformation of invasive lung adenocarcinoma with ALK rearrangement into pulmonary sarcomatoid carcinoma. ⁶²	Xie X...Feng X	35426613	2022
14	Pten and p53 Loss in the Mouse Lung Causes Adenocarcinoma and Sarcomatoid Carcinoma. ⁶²	Lazaro S...Santos M	35954335	2022
15	Lung sarcomatoid carcinoma metastases to the hepatic flexure, the mesenteric and adrenal glands: A case report. ⁶²	Zhang SM...Zhao ZG	35864043	2022
16	Commentary: Resected pulmonary sarcomatoid carcinoma-a defined treatment paradigm, or just the end of the beginning of the search? ⁶²	Batchelor TJP	33812685	2022
17	Adjuvant chemotherapy for pulmonary sarcomatoid carcinoma: A retrospective analysis of the National Cancer Database. ⁶²	Abdallah HM...Okusanya OT	33678508	2022
18	Clinical and pathological characteristics of 11 NSCLC patients with c-MET exon 14 skipping. ⁶²	Chen H...Yang Z	35571650	2022
19	Phase II study of carboplatin-paclitaxel alone or with bevacizumab in advanced sarcomatoid carcinoma of the lung: HOT1201/NEJ024. ⁶²	Oizumi S...North East Japan Study Group, Hokkaido Lung Cancer Clinical Study Group	35092535	2022
20	Pulmonary Sarcomatoid Carcinoma With Epiglottis and Ileum Metastasis Detected by 18F-FDG PET/CT. ⁶²	Gao C...Liu H	34653056	2022
21	The treatment of advanced pulmonary sarcomatoid carcinoma. ⁶²	Zheng Y...Zhang Y	34879738	2022
22	Use of PD-1 inhibitor tislelizumab in the treatment of advanced pulmonary sarcomatoid carcinoma: A case report. ⁶²	Xu L...Su LL	34953097	2022
23	The Prognosis of Pulmonary Sarcomatoid Carcinoma: Development and Validation of a Nomogram Based on SEER. ⁶²	Xie Y...Gu L	35730203	2022
24	Loss of Methylthioadenosine Phosphorylase by Immunohistochemistry Is Common in Pulmonary Sarcomatoid Carcinoma and Sarcomatoid Mesothelioma. ⁶²	Terra S...Boland JM	34463336	2022
25	A case of PD-L1 negative advanced pulmonary sarcomatoid carcinoma effectively treated with atezolizumab, carboplatin, paclitaxel, and bevacizumab. ⁶²	Sawatari K...Mamoto T	35059287	2022
26	Immunophenotyping of pulmonary sarcomatoid carcinoma. ⁶²	Ma Y...Zhu J	36341325	2022
27	Circulating tumour DNA biomarkers in savolitinib-treated patients with non-small cell lung cancer harbouring MET exon 14 skipping alterations: a post hoc analysis of a pivotal phase 2 study. ⁶²	Yu Y...Lu S	36339926	2022
28	Characteristics and clinical outcomes of pulmonary sarcomatoid carcinoma: experience from Tata Memorial Centre. ⁶²	Bondili SK...Prabhash K	36200011	2022
29	Treatment of Multiple Primary Malignancies With PD-1 Inhibitor Camrelizumab: A Case Report and Brief Literature Review. ⁶²	Wan Y...Liu F	35865468	2022
30	Significant response of pulmonary sarcomatoid carcinoma with obstructive atelectasis to treatment with the PD-1 inhibitor camrelizumab combined with transbronchial cryoablation: A case report and literature review. ⁶²	Nian J...Wang X	36387200	2022
31	Immune checkpoint inhibitors plus chemotherapy in patients with locally advanced or metastatic pulmonary sarcomatoid carcinoma: a multicentric real-world study. ⁶²	Zhou F...Zhou C	36419724	2022
32	MET alterations in advanced pulmonary sarcomatoid carcinoma. ⁶²	Gong C...Zhang J	36212500	2022
33	Adjuvant chemotherapy is not a decisive factor in improving the overall survival of pulmonary sarcoma: A population-based study. ⁶²	Liang L...Xie S	36091171	2022
34	The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma. ⁶²	Qian X...Li Y	36389780	2022
35	Real-world treatment patterns and outcomes among patients with advanced non-small-cell lung cancer with spindle cell and/or giant cell carcinoma. ⁶²	Chang CL...Yu CJ	36324732	2022
36	Establishment of a Competing Risk Nomogram in Patients with Pulmonary Sarcomatoid Carcinoma. ⁶²	Liang Z...Yao J	35179409	2022
37	Characteristics and Prognostic Analysis of 55 Patients With Pulmonary Sarcomatoid Carcinoma. ⁶²	Sun J...Chang B	35592676	2022
38	KRAS Mutation in Rare Tumors: A Landscape Analysis of 3453 Chinese Patients. ⁶²	Wang S...Li N	35359599	2022
39	Case Report: Pulmonary sarcomatoid carcinoma complicating TP53 mutation treated successfully with Tislelizumab combined with Anlotinib-a case report. ⁶²	Li YF...Shen H	35938033	2022
40	Genomic Variations and Immune-Related Features of TMB, PD-L1 Expression and CD8+ T Cell Infiltration in Chinese Pulmonary Sarcomatoid Carcinoma. ⁶²	Zhang C...Wang H	35480996	2022
41	Treatment Response to Immunotherapy After Crizotinib Resistance in a Patient With Pulmonary Sarcomatoid Carcinoma Harboring MET Exon 14 Skipping Mutation: A Case Report. ⁶²	Gu L...Heng W	35110965	2022
42	Multimodality Treatment of Pulmonary Sarcomatoid Carcinoma: A Review of Current State of Art. ⁶²	Zhang L...He J	35368903	2022
43	Thoracic mesenchymal malignant tumors and programed cell death ligand-1 status: Clinicopathologic and prognostic analysis of eight pulmonary sarcomatoid carcinomas and eight malignant mesotheliomas. ⁶²	Otsubo K...Saji H	34655161	2021
44	Pulmonary sarcomatoid carcinoma mimicking pleural mesothelioma: A case report. ⁶²	Wang L...Cao J	34766593	2021
45	Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study. ⁶²	Lu S...Su W	34166627	2021
46	Savolitinib: First Approval. ⁶²	Markham A	34455538	2021
47	Rapidly Progressive Lung Sarcomatoid Carcinoma Managed with Doxorubicin Plus Ifosfamide and Pemetrexed. ⁶²	Paredes Mogica JA...Magallanes Maciel ME	35082625	2021
48	Duodenal Metastasis of Pulmonary Pleomorphic Carcinoma: A Case Report. ⁶²	Matsuda M...Muro S	34899244	2021
49	Correction to: GATA3 is a useful immunohistochemical marker for distinguishing sarcomatoid malignant mesothelioma from lung sarcomatoid carcinoma and organizing pleuritis. ⁶²	Piao ZH...Chen JY	33712881	2021
50	GATA3 is a useful immunohistochemical marker for distinguishing sarcomatoid malignant mesothelioma from lung sarcomatoid carcinoma and organizing pleuritis. ⁶²	Piao ZH...Chen JY	33570661	2021

Sources

Genes for Lung Sarcomatoid Carcinoma

Genes related to Lung Sarcomatoid Carcinoma (0 elite genes):

(show all 17)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	KDM4C	Lysine Demethylase 4C	Protein Coding	12.02	DISEASES inferred ¹⁴ ¹⁴
2	ALK	ALK Receptor Tyrosine Kinase	Protein Coding	6.71	DISEASES inferred ¹⁴
3	CD274	CD274 Molecule	Protein Coding	6.38	DISEASES inferred ¹⁴
4	ROS1	ROS Proto-Oncogene 1, Receptor Tyrosine Kinase	Protein Coding	6.3	DISEASES inferred ¹⁴
5	EGFR	Epidermal Growth Factor Receptor	Protein Coding	6.24	DISEASES inferred ¹⁴
6	KRAS	KRAS Proto-Oncogene, GTPase	Protein Coding	6.21	DISEASES inferred ¹⁴
7	NKX2-1	NK2 Homeobox 1	Protein Coding	6.09	DISEASES inferred ¹⁴
8	CALB2	Calbindin 2	Protein Coding	6.06	DISEASES inferred ¹⁴
9	HRAS	HRas Proto-Oncogene, GTPase	Protein Coding	6	DISEASES inferred ¹⁴
10	LINC01435	Long Intergenic Non-Protein Coding RNA 1435	RNA Gene	5.97	DISEASES inferred ¹⁴
11	NAPSA	Napsin A Aspartic Peptidase	Protein Coding	5.94	DISEASES inferred ¹⁴
12	KRT5	Keratin 5	Protein Coding	5.8	DISEASES inferred ¹⁴
13	EML4	EMAP Like 4	Protein Coding	5.77	DISEASES inferred ¹⁴
14	KRT7	Keratin 7	Protein Coding	5.74	DISEASES inferred ¹⁴
15	MET	MET Proto-Oncogene, Receptor Tyrosine Kinase	Protein Coding	5.56	DISEASES inferred ¹⁴
16	NKX2-4	NK2 Homeobox 4	Protein Coding	5.51	DISEASES inferred ¹⁴
17	RET	Ret Proto-Oncogene	Protein Coding	5.49	DISEASES inferred ¹⁴

Sources

Variations for Lung Sarcomatoid Carcinoma

Cosmic variations for Lung Sarcomatoid Carcinoma:

⁸ (show top 50) (show all 2250)

#	Cosmic Mut ID	Gene Symbol	COSMIC Disease Classification (Primary site, Site subtype, Primary histology, Histology subtype)	Mutation CDS	Mutation AA	GRCh38 Location	Conf
1	COSM143166546	VEGFA	lung,NS,carcinoma,sarcomatoid carcinoma	c.823G>T	p.V275L	6:43777633-43777633	13
2	COSM144539293	VEGFA	lung,NS,carcinoma,sarcomatoid carcinoma	c.823G>T	p.V275L	6:43777633-43777633	13
3	COSM106394496	VEGFA	lung,NS,carcinoma,sarcomatoid carcinoma	c.823G>T	p.V275L	6:43777633-43777633	13
4	COSM112509623	VEGFA	lung,NS,carcinoma,sarcomatoid carcinoma	c.283G>T	p.V95L	6:43777633-43777633	13
5	COSM128143392	VEGFA	lung,NS,carcinoma,sarcomatoid carcinoma	c.283G>T	p.V95L	6:43777633-43777633	13
6	COSM97205442	VEGFA	lung,NS,carcinoma,sarcomatoid carcinoma	c.283G>T	p.V95L	6:43777633-43777633	13
7	COSM128342331	VEGFA	lung,NS,carcinoma,sarcomatoid carcinoma	c.283G>T	p.V95L	6:43777633-43777633	13
8	COSM142955742	VEGFA	lung,NS,carcinoma,sarcomatoid carcinoma	c.823G>T	p.V275L	6:43777633-43777633	13
9	COSM146194764	VEGFA	lung,NS,carcinoma,sarcomatoid carcinoma	c.823G>T	p.V275L	6:43777633-43777633	13
10	COSM147030479	VEGFA	lung,NS,carcinoma,sarcomatoid carcinoma	c.823G>T	p.V275L	6:43777633-43777633	13
11	COSM128500813	VEGFA	lung,NS,carcinoma,sarcomatoid carcinoma	c.283G>T	p.V95L	6:43777633-43777633	13
12	COSM97165521	VEGFA	lung,NS,carcinoma,sarcomatoid carcinoma	c.823G>T	p.V275L	6:43777633-43777633	13
13	COSM105692110	VEGFA	lung,NS,carcinoma,sarcomatoid carcinoma	c.823G>T	p.V275L	6:43777633-43777633	13
14	COSM107300017	VEGFA	lung,NS,carcinoma,sarcomatoid carcinoma	c.823G>T	p.V275L	6:43777633-43777633	13
15	COSM97173559	VEGFA	lung,NS,carcinoma,sarcomatoid carcinoma	c.823G>T	p.V275L	6:43777633-43777633	13
16	COSM142535359	VEGFA	lung,NS,carcinoma,sarcomatoid carcinoma	c.823G>T	p.V275L	6:43777633-43777633	13
17	COSM146259120	VEGFA	lung,NS,carcinoma,sarcomatoid carcinoma	c.823G>T	p.V275L	6:43777633-43777633	13
18	COSM127348533	VEGFA	lung,NS,carcinoma,sarcomatoid carcinoma	c.283G>T	p.V95L	6:43777633-43777633	13
19	COSM118539070	VEGFA	lung,NS,carcinoma,sarcomatoid carcinoma	c.823G>T	p.V275L	6:43777633-43777633	13
20	COSM126890772	VEGFA	lung,NS,carcinoma,sarcomatoid carcinoma	c.283G>T	p.V95L	6:43777633-43777633	13
21	COSM128632965	VEGFA	lung,NS,carcinoma,sarcomatoid carcinoma	c.283G>T	p.V95L	6:43777633-43777633	13
22	COSM88794233	VEGFA	lung,NS,carcinoma,sarcomatoid carcinoma	c.823G>T	p.V275L	6:43777633-43777633	13
23	COSM84939935	VEGFA	lung,NS,carcinoma,sarcomatoid carcinoma	c.199G>T	p.V67L	6:43777633-43777633	13
24	COSM97138403	VEGFA	lung,NS,carcinoma,sarcomatoid carcinoma	c.823G>T	p.V275L	6:43777633-43777633	13
25	COSM131095609	TSHR	lung,NS,carcinoma,sarcomatoid carcinoma	c.2082C>G	p.S694R	14:81144140-81144140	13
26	COSM85479420	TSHR	lung,NS,carcinoma,sarcomatoid carcinoma	c.2082C>G	p.S694R	14:81144140-81144140	13
27	COSM93231483	TP53	lung,NS,carcinoma,sarcomatoid carcinoma	c.490A>T	p.K164*	17:7675122-7675122	13
28	COSM93189061	TP53	lung,NS,carcinoma,sarcomatoid carcinoma	c.782+1G>T	p.?	17:7674180-7674180	13
29	COSM143415517	TP53	lung,NS,carcinoma,sarcomatoid carcinoma	c.373A>T	p.K125*	17:7675122-7675122	13
30	COSM112289613	TP53	lung,NS,carcinoma,sarcomatoid carcinoma	c.482C>A	p.A161D	17:7675130-7675130	13
31	COSM144046484	TP53	lung,NS,carcinoma,sarcomatoid carcinoma	c.449C>A	p.A150D	17:7675130-7675130	13
32	COSM106053037	TP53	lung,NS,carcinoma,sarcomatoid carcinoma	c.659A>G	p.Y220C	17:7674872-7674872	13
33	COSM143943655	TP53	lung,NS,carcinoma,sarcomatoid carcinoma	c.182A>G	p.Y61C	17:7674872-7674872	13
34	COSM122739428	TP53	lung,NS,carcinoma,sarcomatoid carcinoma	c.386+1G>T	p.?	17:7674180-7674180	13
35	COSM143187727	TP53	lung,NS,carcinoma,sarcomatoid carcinoma	c.5C>A	p.A2D	17:7675130-7675130	13
36	COSM121875754	TP53	lung,NS,carcinoma,sarcomatoid carcinoma	c.263A>G	p.Y88C	17:7674872-7674872	13
37	COSM144310046	TP53	lung,NS,carcinoma,sarcomatoid carcinoma	c.542A>G	p.Y181C	17:7674872-7674872	13
38	COSM144650895	TP53	lung,NS,carcinoma,sarcomatoid carcinoma	c.542A>G	p.Y181C	17:7674872-7674872	13
39	COSM112258683	TP53	lung,NS,carcinoma,sarcomatoid carcinoma	c.782+1G>T	p.?	17:7674180-7674180	13
40	COSM145050841	TP53	lung,NS,carcinoma,sarcomatoid carcinoma	c.365C>A	p.A122D	17:7675130-7675130	13
41	COSM142874218	TP53	lung,NS,carcinoma,sarcomatoid carcinoma	c.490A>T	p.K164*	17:7675122-7675122	13
42	COSM144013214	TP53	lung,NS,carcinoma,sarcomatoid carcinoma	c.626A>G	p.Y209C	17:7674872-7674872	13
43	COSM122772989	TP53	lung,NS,carcinoma,sarcomatoid carcinoma	c.86C>A	p.A29D	17:7675130-7675130	13
44	COSM106089182	TP53	lung,NS,carcinoma,sarcomatoid carcinoma	c.482C>A	p.A161D	17:7675130-7675130	13
45	COSM143370705	TP53	lung,NS,carcinoma,sarcomatoid carcinoma	c.542A>G	p.Y181C	17:7674872-7674872	13
46	COSM144114793	TP53	lung,NS,carcinoma,sarcomatoid carcinoma	c.5C>A	p.A2D	17:7675130-7675130	13
47	COSM144338406	TP53	lung,NS,carcinoma,sarcomatoid carcinoma	c.365C>A	p.A122D	17:7675130-7675130	13
48	COSM144348052	TP53	lung,NS,carcinoma,sarcomatoid carcinoma	c.373A>T	p.K125*	17:7675122-7675122	13
49	COSM122784424	TP53	lung,NS,carcinoma,sarcomatoid carcinoma	c.94A>T	p.K32*	17:7675122-7675122	13
50	COSM111795092	TP53	lung,NS,carcinoma,sarcomatoid carcinoma	c.482C>A	p.A161D	17:7675130-7675130	13

Sources

Expression for Lung Sarcomatoid Carcinoma

Search GEO for disease gene expression data for Lung Sarcomatoid Carcinoma.

Sources

Pathways for Lung Sarcomatoid Carcinoma

Pathways related to Lung Sarcomatoid Carcinoma according to GeneCards Suite gene sharing:

(show all 29)

#	Super pathways	Score	Top Affiliating Genes
1	Signal Transduction ⁶⁶	13.65	RET MET KRAS KDM4C HRAS EGFR
2	RAF/MAP kinase cascade ⁶⁶ Show member pathways Diseases of signal transduction by growth factor receptors and second messengers ⁶⁶ MAPK family signaling cascades ⁶⁶ MAPK1/MAPK3 signaling ⁶⁶	13.21	ALK EGFR EML4 HRAS KRAS MET
3	CREB Pathway ⁶⁴ Show member pathways Activation of PKC through GPCR ⁶⁴ Intracellular Calcium Signaling ⁶⁴ IP3 Pathway ⁶⁴	13.19	ROS1 MET KRAS HRAS EGFR ALK
4	Nanog in Mammalian ESC Pluripotency ⁶⁴ Show member pathways 14-3-3 Induced Intracellular Signaling ⁶⁴ eNOS Signaling ⁶⁴ GSK3 Signaling ⁶⁴	13.13	ALK EGFR HRAS KRAS MET ROS1
5	Signaling by Receptor Tyrosine Kinases ⁶⁶	12.56	ALK CD274 EGFR HRAS KRAS MET
6	Endometrial cancer ⁷⁴ Show member pathways Chromosomal and microsatellite instability in colorectal cancer ⁷⁴ Melanoma ⁷⁴ Non-small cell lung cancer ⁷⁴ Pancreatic adenocarcinoma pathway ⁷⁴ Signal transduction PTEN pathway ²²	12.53	KRAS HRAS EML4 EGFR ALK
7	NF-kappaB Pathway ⁷⁰ Show member pathways Akt Pathway ⁷⁰ Apoptosis Pathway ⁷⁰	12.29	MET KRAS HRAS EGFR
8	Ras signaling ⁷⁴	12.09	MET KRAS HRAS EGFR
9	G-protein signaling RAC1 in cellular process ²² Show member pathways CDC42 signaling events ⁶¹ Cytoskeleton remodeling CDC42 in cellular processes ²² RAC1 signaling pathway ⁶¹	12.08	ROS1 MET KRAS HRAS EGFR ALK
10	MAPK Signaling: Mitogens ⁶⁵ Show member pathways Akt Signaling Pathway ⁶⁵	12.07	MET KRAS HRAS EGFR
11	Signaling by ERBB2 ⁶⁶ Show member pathways Downregulation of ERBB2 signaling ⁶⁶ Downregulation of ERBB2:ERBB3 signaling ⁶⁶ ERBB2 Activates PTK6 Signaling ⁶⁶ ERBB2 Regulates Cell Motility ⁶⁶ GRB7 events in ERBB2 signaling ⁶⁶	11.92	KRAS HRAS EGFR
12	Gastrin signaling pathway ⁷⁴	11.85	KRAS HRAS EGFR
13	Development EGFR signaling via small GTPases ²² Show member pathways Development EGFR signaling via PIP3 ²² Development PDGF signaling via MAPK cascades ²²	11.85	KRAS HRAS EGFR
14	Tyrosine Kinases / Adaptors ³	11.82	ROS1 RET MET EGFR ALK
15	Signaling by EGFR ⁶⁶ Show member pathways EGFR downregulation ⁶⁶ GAB1 signalosome ⁶⁶	11.77	KRAS HRAS EGFR
16	VEGF Pathway (Tocris) ⁷⁰ Show member pathways Sorafenib Pharmacodynamics ⁶⁰	11.64	RET KRAS HRAS
17	Head and neck squamous cell carcinoma ⁷⁴	11.6	KRAS HRAS EGFR
18	Agrin Interactions at Neuromuscular Junction ⁶⁴	11.47	KRAS HRAS EGFR
19	Vemurafenib Pathway, Pharmacodynamics ⁶⁰	11.3	KRAS HRAS EGFR
20	Bladder cancer ⁷⁴	11.26	KRAS HRAS EGFR
21	Transcription_Transcription factor Tubby signaling pathways ²²	11.2	KRAS HRAS EGFR
22	a6b1 and a6b4 Integrin signaling ⁶¹	11.2	MET HRAS EGFR
23	Posttranslational regulation of adherens junction stability and dissassembly ⁶¹	11.14	RET MET HRAS EGFR
24	Aryl hydrocarbon receptor pathway ⁷⁴	11.09	KRAS HRAS EGFR
25	Gastrin-CREB signalling pathway via PKC and MAPK ⁶⁶ Show member pathways EGFR Transactivation by Gastrin ⁶⁶	11.01	KRAS HRAS EGFR
26	ERK pathway in Huntington's disease ⁷⁴	10.79	HRAS EGFR
27	Extracellular vesicle-mediated signaling in recipient cells ⁷⁴	10.7	MET KRAS HRAS EGFR
28	Crizotinib Pathway, Pharmacokinetics/Pharmacodynamics ⁶⁰	10.68	ROS1 MET KRAS HRAS EML4 ALK
29	TNF-alpha signaling pathway ⁷⁴ Show member pathways RAS GTPase cycle mutants ⁶⁶ Signaling by RAS GAP mutants ⁶⁶ Signaling by RAS GTPase mutants ⁶⁶	10.67	KRAS HRAS

Sources

GO Terms for Lung Sarcomatoid Carcinoma

Cellular components related to Lung Sarcomatoid Carcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	receptor complex	GO:0043235	9.32	ROS1 RET MET EGFR ALK

Biological processes related to Lung Sarcomatoid Carcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	MAPK cascade	GO:0000165	9.97	RET KRAS HRAS EGFR
2	peptidyl-tyrosine phosphorylation	GO:0018108	9.91	ROS1 RET MET EGFR ALK
3	transmembrane receptor protein tyrosine kinase signaling pathway	GO:0007169	9.85	ALK EGFR MET RET ROS1
4	peptidyl-tyrosine autophosphorylation	GO:0038083	9.72	ROS1 EGFR ALK
5	positive regulation of kinase activity	GO:0033674	9.65	ROS1 RET MET EGFR ALK
6	multicellular organism development	GO:0007275	9.02	ROS1 RET MET EGFR ALK

Molecular functions related to Lung Sarcomatoid Carcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	protein tyrosine kinase activity	GO:0004713	9.65	ROS1 RET MET EGFR ALK
2	protein kinase activity	GO:0004672	9.55	ROS1 RET MET EGFR ALK
3	transmembrane receptor protein tyrosine kinase activity	GO:0004714	9.32	ROS1 RET MET EGFR ALK

Sources

Sources for Lung Sarcomatoid Carcinoma

¹ BitterDB

² CDC

³ Cell Signaling Technology

⁴ ClinicalTrials

⁵ ClinVar

⁶ CNVD

⁷ Cochrane Library

⁸ Cosmic

⁹ dbSNP

¹⁰ DGIdb

¹¹ Disease Ontology

¹² diseasecard

¹³ DiseaseEnhancer

¹⁴ DISEASES

¹⁵ DrugBank

¹⁶ EFO

¹⁷ ExPASy

¹⁸ FMA

¹⁹ GARD

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ GenomeRNAi

²⁶ GEO DataSets

²⁷ GO

²⁸ GTR

²⁹ HMDB

³⁰ HPO

³¹ ICD10

³² ICD10 via Orphanet

³³ ICD11

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ LifeMap

³⁷ LncRNADisease

³⁸ LOVD

³⁹ MalaCards

⁴⁰ MedGen

⁴¹ MedlinePlus

⁴² MedlinePlus Genetics

⁴³ MeSH

⁴⁴ MESH via Orphanet

⁴⁵ MGI

⁴⁶ miR2Disease

⁴⁷ NCBI Bookshelf

⁴⁸ NCI

⁴⁹ NCIt

⁵⁰ NDF-RT

⁵¹ NIH Clinical Center

⁵² NINDS

⁵³ Novoseek

⁵⁴ Novus Biologicals

⁵⁵ ODiseA

⁵⁶ OMIM via Orphanet

⁵⁷ OMIM® (Updated 08-Dec-2022)

⁵⁸ Orphanet

⁵⁹ PathCards

⁶⁰ PharmGKB

⁶¹ PubChem

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ Tocris

⁷¹ UMLS

⁷² UMLS via Orphanet

⁷³ UniProtKB/Swiss-Prot

⁷⁴ WikiPathways

⁷⁵ Wikipedia

MCID: LNG115 MIFTS: 50	Lung Sarcomatoid Carcinoma Categories: Cancer diseases, Respiratory diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Drugs Expand all tables